Indian company Hetero COVID-19 Oral Drug Nirmacom gets WHO prequalification

Covid-19 Oral Antiviral Treatments: The World Health Organization (WHO) has approved a new drug manufactured by India’s leading pharmaceutical company, Hetero, to prevent the coronavirus. The generic version of Hetero’s oral Kovid-19 antiviral treatment, Nirmatrelvir, which the company has described as useful in the fight against the coronavirus, has arrived. However, people will get this drug only on the recommendation of a doctor. Hetero has launched a combination pack in the form of an oral drug ‘Nirmacom’.

The World Health Organization (WHO) has said that India’s leading pharmaceutical company Hetero has manufactured a drug to prevent the corona epidemic. Hetero’s ‘Nirmacom’ is the generic version of Pfizer’s Kovid-19 oral antiviral drug ‘Paxlovid’. Today it is a good therapeutic option for high-risk patients. However, the patient should take it only on the advice of the doctor.

Kovid will help in the war.

Dr. Vamsi Krishna Bandi, Managing Director of Hetero Group of Companies in India, said that the generic version of our Kovid-19 oral antiviral treatment, Nirmatrelvir ‘Nirmacom’, has been approved by the WHO. He said that this medicine will be useful in the fight against Kovid. Dr Vamsi said: “Getting our medicine prequalified by WHO is an important milestone in the fight against COVID-19, as it allows us to bring this innovative antiretroviral medicine to those who need it.”

Focus on providing medicines at affordable prices

Dr Vamsi said: “WHO has recommended Nirmatrelvir and Ritonavir for high-risk hospitalized patients, as well as moderate- and low-risk Covid patients. We expect Nirmacom to be quickly available in 95 LMICs at affordable prices. We are committed to.” At the same time, in the statement from India’s leading pharmaceutical company, Hetero, it was also reported that the World Health Organization Drug Prequalification Program (WHO PQ) has approved the genetic version of our oral antiviral treatment Nirmatelvir, necessary to deal with COVID-19. 19 It was said on behalf of the company that now the scope of our medicine will also be extended.

Also read: From China to Japan… RT-PCR test is necessary for passengers from these countries, immediate quarantine if positive


Exit mobile version